Exagen Inc

Our mission is to bring clarity to complex autoimmune diseases by empowering physicians, and our partners across healthcare and biopharma, with advanced testing solutions that enable earlier, more accurate diagnoses and better patient outcomes. Through our AVISE® testing portfolio, we deliver the industry’s most comprehensive rheumatology diagnostic platform — integrating serology, cell-based assays, proprietary biomarkers, and a validated algorithm. Exagen is the only company to offer CB-CAPS, T Cell markers, anti-PAD4 and anti-RA33 testing commercially, and the pioneer in clinically validating these biomarkers for SLE and rheumatoid arthritis (RA), respectively. We also provide the industry’s leading lupus (SLE) diagnostic, prognostic, and disease-monitoring tests, setting the benchmark for accuracy and clinical confidence. By combining scientific rigor with compassion for patients, Exagen partners with physicians, payers, and biopharmaceutical companies to close diagnostic gaps, accelerate innovation, and redefine what’s possible in autoimmune care For more information on our company, please visit For more information on AVISE testing services, please visit Social Media Terms of Use: http://bit.ly/smtou